DE10313791A1 - Spezifischer Nachweis von Mykobakterien des M. tuberculosis-Komplex - Google Patents
Spezifischer Nachweis von Mykobakterien des M. tuberculosis-Komplex Download PDFInfo
- Publication number
- DE10313791A1 DE10313791A1 DE10313791A DE10313791A DE10313791A1 DE 10313791 A1 DE10313791 A1 DE 10313791A1 DE 10313791 A DE10313791 A DE 10313791A DE 10313791 A DE10313791 A DE 10313791A DE 10313791 A1 DE10313791 A1 DE 10313791A1
- Authority
- DE
- Germany
- Prior art keywords
- seq
- pair
- specific
- nucleotide sequences
- tuberculosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000011895 specific detection Methods 0.000 title claims abstract description 38
- 241001302239 Mycobacterium tuberculosis complex Species 0.000 title claims abstract description 6
- 201000008827 tuberculosis Diseases 0.000 claims abstract description 84
- 238000000034 method Methods 0.000 claims abstract description 59
- 241001467552 Mycobacterium bovis BCG Species 0.000 claims abstract description 54
- 241000186366 Mycobacterium bovis Species 0.000 claims abstract description 48
- 241000187919 Mycobacterium microti Species 0.000 claims abstract description 31
- 241001467553 Mycobacterium africanum Species 0.000 claims abstract description 29
- 239000000523 sample Substances 0.000 claims description 131
- 238000009396 hybridization Methods 0.000 claims description 128
- 108020004414 DNA Proteins 0.000 claims description 100
- 239000012634 fragment Substances 0.000 claims description 88
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 86
- 125000003729 nucleotide group Chemical group 0.000 claims description 61
- 239000002773 nucleotide Substances 0.000 claims description 60
- 244000052769 pathogen Species 0.000 claims description 54
- 230000003321 amplification Effects 0.000 claims description 53
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 53
- 230000000295 complement effect Effects 0.000 claims description 48
- 238000001514 detection method Methods 0.000 claims description 35
- 239000012568 clinical material Substances 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 108091034117 Oligonucleotide Proteins 0.000 claims description 24
- 241000283690 Bos taurus Species 0.000 claims description 17
- 108090000913 Nitrate Reductases Proteins 0.000 claims description 17
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims description 17
- 101150114893 oxyR gene Proteins 0.000 claims description 17
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 15
- 238000003752 polymerase chain reaction Methods 0.000 claims description 15
- 208000015181 infectious disease Diseases 0.000 claims description 14
- 230000000813 microbial effect Effects 0.000 claims description 14
- 150000007523 nucleic acids Chemical group 0.000 claims description 14
- 238000011880 melting curve analysis Methods 0.000 claims description 13
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 12
- 241000186359 Mycobacterium Species 0.000 claims description 10
- 238000003753 real-time PCR Methods 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 238000001574 biopsy Methods 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 238000011144 upstream manufacturing Methods 0.000 claims description 5
- 206010036790 Productive cough Diseases 0.000 claims description 4
- 108091081024 Start codon Proteins 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 210000004051 gastric juice Anatomy 0.000 claims description 4
- 210000003802 sputum Anatomy 0.000 claims description 4
- 208000024794 sputum Diseases 0.000 claims description 4
- 238000013519 translation Methods 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 238000001917 fluorescence detection Methods 0.000 claims 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 abstract description 4
- 239000012472 biological sample Substances 0.000 abstract 1
- 239000013615 primer Substances 0.000 description 91
- 230000001717 pathogenic effect Effects 0.000 description 37
- 238000002844 melting Methods 0.000 description 28
- 230000008018 melting Effects 0.000 description 28
- 241000894007 species Species 0.000 description 28
- 108020004707 nucleic acids Proteins 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 238000013459 approach Methods 0.000 description 10
- 206010062207 Mycobacterial infection Diseases 0.000 description 9
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000000692 anti-sense effect Effects 0.000 description 7
- 239000000975 dye Substances 0.000 description 6
- 238000007403 mPCR Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical class [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 4
- 241000186367 Mycobacterium avium Species 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 241000186361 Actinobacteria <class> Species 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- 241000186781 Listeria Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000187482 Mycobacterium avium subsp. paratuberculosis Species 0.000 description 2
- 241000186364 Mycobacterium intracellulare Species 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 244000053095 fungal pathogen Species 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010044756 Tuberculous infections Diseases 0.000 description 1
- 238000007844 allele-specific PCR Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 101150114864 plcA gene Proteins 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 229960002109 tuberculosis vaccine Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10313791A DE10313791A1 (de) | 2003-03-20 | 2003-03-20 | Spezifischer Nachweis von Mykobakterien des M. tuberculosis-Komplex |
| PCT/EP2004/002911 WO2004083459A1 (de) | 2003-03-20 | 2004-03-19 | Verfahren und kit zum spezifischen nachweis von m. tuberculosis |
| CA002519702A CA2519702A1 (en) | 2003-03-20 | 2004-03-19 | Method and kit for the specific detection of m.tuberculosis |
| AU2004221678A AU2004221678B2 (en) | 2003-03-20 | 2004-03-19 | Method and kit for a specific detection of M.tuberculosis |
| US10/549,495 US7749696B2 (en) | 2003-03-20 | 2004-03-19 | Method and kit for the specific detection of M. tuberculosis |
| AT04721892T ATE518964T1 (de) | 2003-03-20 | 2004-03-19 | Verfahren und kit zum spezifischen nachweis von m. tuberculosis |
| EP04721892A EP1606420B1 (de) | 2003-03-20 | 2004-03-19 | Verfahren und kit zum spezifischen nachweis von m. tuberculosis |
| JP2006504758A JP4599346B2 (ja) | 2003-03-20 | 2004-03-19 | ヒト型結核菌の特異的検出のための方法およびキット |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10313791A DE10313791A1 (de) | 2003-03-20 | 2003-03-20 | Spezifischer Nachweis von Mykobakterien des M. tuberculosis-Komplex |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10313791A1 true DE10313791A1 (de) | 2004-10-07 |
Family
ID=32946237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10313791A Withdrawn DE10313791A1 (de) | 2003-03-20 | 2003-03-20 | Spezifischer Nachweis von Mykobakterien des M. tuberculosis-Komplex |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7749696B2 (enExample) |
| EP (1) | EP1606420B1 (enExample) |
| JP (1) | JP4599346B2 (enExample) |
| AT (1) | ATE518964T1 (enExample) |
| AU (1) | AU2004221678B2 (enExample) |
| CA (1) | CA2519702A1 (enExample) |
| DE (1) | DE10313791A1 (enExample) |
| WO (1) | WO2004083459A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009087688A2 (en) * | 2008-01-04 | 2009-07-16 | Premas Biotech Pvt.Ltd | Method for detection of nucleic acid of mycobacterium and uses thereof |
| US20090311677A1 (en) * | 2008-06-13 | 2009-12-17 | Andrew Reeves | Identification of contaminating bacteria in industrial ethanol fermentations |
| WO2014132263A1 (en) * | 2013-02-27 | 2014-09-04 | Council Of Scientific & Industrial Research | Nitrite-reductase (nirb) as potential anti-tubercular target and a method to detect the severity of tuberculosis disease |
| JP2021119751A (ja) * | 2020-01-30 | 2021-08-19 | 東洋紡株式会社 | 微生物の同定方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10014575A1 (de) * | 1999-03-16 | 2000-11-30 | Hans Konrad Schackert | Verfahren zur Identifizierung von Organismen durch vergleichende genetische Analyse sowie Primer und Hybridisationssonden zur Durchführung des Verfahrens |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6294328B1 (en) * | 1998-06-24 | 2001-09-25 | The Institute For Genomic Research | DNA sequences for strain analysis in Mycobacterium tuberculosis |
| US7247430B2 (en) | 2001-08-14 | 2007-07-24 | Institut Pasteur | Compositions and methods for detecting multidrug resistant strains of M. tuberculosis having mutations in genes of the mutT family |
-
2003
- 2003-03-20 DE DE10313791A patent/DE10313791A1/de not_active Withdrawn
-
2004
- 2004-03-19 AT AT04721892T patent/ATE518964T1/de active
- 2004-03-19 AU AU2004221678A patent/AU2004221678B2/en not_active Expired
- 2004-03-19 US US10/549,495 patent/US7749696B2/en active Active
- 2004-03-19 EP EP04721892A patent/EP1606420B1/de not_active Expired - Lifetime
- 2004-03-19 JP JP2006504758A patent/JP4599346B2/ja not_active Expired - Lifetime
- 2004-03-19 CA CA002519702A patent/CA2519702A1/en not_active Abandoned
- 2004-03-19 WO PCT/EP2004/002911 patent/WO2004083459A1/de not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10014575A1 (de) * | 1999-03-16 | 2000-11-30 | Hans Konrad Schackert | Verfahren zur Identifizierung von Organismen durch vergleichende genetische Analyse sowie Primer und Hybridisationssonden zur Durchführung des Verfahrens |
Non-Patent Citations (7)
| Title |
|---|
| MEDLINE AN 1999350091 * |
| MEDLINE AN 1999445192 * |
| MEDLINE AN 2000506545 * |
| MEDLINE AN 2001488171 * |
| Microbiology (2000), 146, 2185-2197 * |
| NCBI AN AD000020 * |
| NCBI AN AY162028 * |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE518964T1 (de) | 2011-08-15 |
| AU2004221678B2 (en) | 2009-04-23 |
| JP2006521797A (ja) | 2006-09-28 |
| US20070015157A1 (en) | 2007-01-18 |
| US7749696B2 (en) | 2010-07-06 |
| EP1606420B1 (de) | 2011-08-03 |
| CA2519702A1 (en) | 2004-09-30 |
| EP1606420A1 (de) | 2005-12-21 |
| AU2004221678A1 (en) | 2004-09-30 |
| JP4599346B2 (ja) | 2010-12-15 |
| WO2004083459A1 (de) | 2004-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69937447T2 (de) | Verfahren zur erkennung von nukleinsäuren | |
| Springer et al. | Two-laboratory collaborative study on identification of mycobacteria: molecular versus phenotypic methods | |
| DE69030131T2 (de) | Erzeugung von spezifischen Sonden gegen Ziel-Nukleotidsequenzen | |
| DE69524083T2 (de) | Stoffen und verfahren zum nachweis von mycobakterium tuberculosis | |
| DE69527154T2 (de) | Spezifische und universelle amplifizierungs-primer zur raschen bestimmung und identifizierung ueblicher bakterieller pathogene und antibiotikaresistenzgene in klinischen proben zur routinediagnose in mikrobiologie-laboratorien | |
| DE60131284T2 (de) | Methode zum nachweis von mikroorganismen | |
| DE69308381T2 (de) | Sonden für Mycobakterien | |
| DE69113261T2 (de) | Hybridizierungssonden von dem abstand zwischen den 16s und 23s rna genen und nachweis von nicht-viralen mikroorganismen. | |
| EP1790735B1 (de) | Oligonukleotide zur schnellen Bestimmung von mikrobieller DNS/RNS | |
| DE60030145T2 (de) | Nachweisverfahren für kurze sequenzvarianten | |
| DE69619845T2 (de) | Verbesserter auf is6110 basierender molekularer nachweis von mycobacterium tuberculosis | |
| WO1999058713A2 (de) | Verfahren zur detektion von mikroorganismen in produkten | |
| DE112013004650T5 (de) | Multiplexpyrosequenzierung unter Verwendung nichtinterferierender, rauschbeendender Polynukleotididentifikationstags | |
| WO2001023606A9 (de) | Nukleinsäuremoleküle zum nachweis von bakterien und phylogenetischen einheiten von bakterien | |
| DE69328951T2 (de) | Nukleinsäuresonden für Mykobacterium Tuberkulosis | |
| DE10215238C1 (de) | Nachweis von Mykobakterien in klinischem Material | |
| DE112020000525T5 (de) | Verfahren zum nachweis mehrerer ziele basierend auf einer einzigennachweissonde unter verwendung eines markierungs-sequenz-snp | |
| DE102007015775A1 (de) | Verfahren zum Nachweis von Paratuberkolose | |
| DE10313791A1 (de) | Spezifischer Nachweis von Mykobakterien des M. tuberculosis-Komplex | |
| DE102015012691A1 (de) | Verfahren zum quantitativen Nachweis von Vibrio parahaemolyticus, Vibrio vulnificus und Vibrio cholerae | |
| DE10392538B4 (de) | Verfahren zur Analyse von methylierten Nukleinsäuren | |
| KR101523877B1 (ko) | 실시간 중합효소연쇄반응법과 융해곡선분석을 이용하는 마이코박테리아의 동정 방법 | |
| DE102011118949B3 (de) | Kombiniertes Verfahren zum differentialdiagnostischen Nachweis von Bakterien des Mycobacterium-tuberculosis-Komplexes und von atypischen Pneumonie-Erregern | |
| EP1390541B1 (de) | Verfahren zum nachweis von gram-positiven bakterien | |
| KR20120113119A (ko) | 실시간 중합효소연쇄반응법과 융해곡선분석을 이용하는 마이코박테리아의 동정 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| R120 | Application withdrawn or ip right abandoned | ||
| R120 | Application withdrawn or ip right abandoned |
Effective date: 20140925 |